Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-07, Vol.389 (1), p.33-44
Hauptverfasser:	Mato, Anthony R., Woyach, Jennifer A., Brown, Jennifer R., Ghia, Paolo, Patel, Krish, Eyre, Toby A., Munir, Talha, Lech-Maranda, Ewa, Lamanna, Nicole, Tam, Constantine S., Shah, Nirav N., Coombs, Catherine C., Ujjani, Chaitra S., Fakhri, Bita, Cheah, Chan Y., Patel, Manish R., Alencar, Alvaro J., Cohen, Jonathon B., Gerson, James N., Flinn, Ian W., Ma, Shuo, Jagadeesh, Deepa, Rhodes, Joanna M., Hernandez-Ilizaliturri, Francisco, Zinzani, Pier L., Seymour, John F., Balbas, Minna, Nair, Binoj, Abada, Paolo, Wang, Chunxiao, Ruppert, Amy S., Wang, Denise, Tsai, Donald E., Wierda, William G., Jurczak, Wojciech
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Anticoagulants Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use B-cell lymphoma Bleeding Bruton's tyrosine kinase Cancer Chronic lymphocytic leukemia Confidence intervals Disease Drug dosages Enrollments FDA approval Hematology Hemorrhage Hemorrhage - chemically induced Humans Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphocytes B Lymphocytosis Lymphoma Neutropenia Neutropenia - chemically induced Oncology Patients Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Statistical analysis Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2300696